HDAC inhibitors have demonstrated great advantages in the treatment of hematologic tumors; in some patients with peripheral T-cell lymphoma, HDAC inhibitors resulted in longer remissions, with durations of up to 48 months [230]. This evidence concerns the gene HDAC9 and peripheral T-cell lymphoma, not otherwise specified.